Pranlukast

RESPIRATORY SYSTEM

Key facts

Pranlukast is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2007. DrugCentral lists 7 molecular targets, including CYSLTR1, CYSLTR1 and CYSLTR2. Recorded indications include Allergic rhinitis and Asthma.

• Molecular targets: CYSLTR1, CYSLTR1, CYSLTR2 and GPR17 (7 listed in DrugCentral).
• Indications: Allergic rhinitis and Asthma.
• ATC code: R03DC02 (Leukotriene receptor antagonists).
• Molecular formula: C27H23N5O4; molecular weight 481.51 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Allergic rhinitis
• Asthma

Mechanism & targets

Molecular targets (7)

Target	Gene	Action	Activity
Cysteinyl leukotriene receptor 1	CYSLTR1	antagonist	IC50 10.00
Cysteinyl leukotriene receptor 1	CYSLTR1	unknown	Ki 9.10
Cysteinyl leukotriene receptor 2	CYSLTR2	antagonist	IC50 5.44
Uracil nucleotide/cysteinyl leukotriene receptor	GPR17	unknown	Ki 5.39
Cruzipain	—	unknown	IC50 5.15
Replicase polyprotein 1ab	rep	unknown	Kd 4.85
Bile acid receptor	NR1H4	unknown	EC50 4.82

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2007-03-15	PMDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
R03DC02	RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › Leukotriene receptor antagonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Hepatic function abnormal	63.5
Upper respiratory tract inflammation	49.6
Pneumonia	42.3
Pyrexia	39.3
Eosinophilic granulomatosis with polyangiitis	38.8
Asthma	37.8
Concomitant disease aggravated	34.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Pranlukast is on its molecule page.

• Molecular formula: C₂₇H₂₃N₅O₄
• Molecular weight: 481.51 g/mol
• CAS number: 103177-37-3
• InChIKey: NBQKINXMPLXUET-UHFFFAOYSA-N
• PubChem CID: 4887

O=C(NC1=CC=CC2=C1OC(=CC2=O)C1=NN=NN1)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Pranlukast used for?

DrugCentral lists the following indications for Pranlukast: Allergic rhinitis and Asthma.

How does Pranlukast work?

Its molecular targets in DrugCentral include CYSLTR1 (antagonist), CYSLTR1, CYSLTR2 (antagonist) and GPR17.

When was Pranlukast first approved?

Pranlukast was first approved by the PMDA in 2007.

What is the chemical formula of Pranlukast?

Pranlukast has the molecular formula C27H23N5O4 and a molecular weight of 481.51 g/mol.

Sources

• DrugCentral drug card 2237 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL11350 — compound record and bioactivity
• PubChem CID 4887 — chemical identifiers
• DrugBank DB01411 — drug record
• FDA UNII TB8Z891092 — substance identity
• UniProt Q9Y271 (CYSLTR1) — target protein
• UniProt Q9NS75 (CYSLTR2) — target protein
• UniProt Q13304 (GPR17) — target protein
• UniProt Q96RI1 (NR1H4) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.